For a patient being discharged after treatment for acute decompensated heart failure, which intervention is recommended to prevent readmission?

Starting empagliflozin 10 mg daily is a recommended intervention for patients being discharged after treatment for acute decompensated heart failure to prevent readmission. Empagliflozin, an SGLT2 (sodium-glucose co-transporter 2) inhibitor, has been shown to reduce the risk of hospitalization for heart failure and improve overall outcomes in patients with heart failure with reduced ejection fraction (HFrEF). By providing diuresis and improving cardiac function, SGLT2 inhibitors contribute valuable benefits beyond just glycemic control, particularly in reducing heart failure exacerbations.

In contrast, continuing intravenous diuresis until discharge is not suitable for long-term management post-discharge, as intravenous therapies are typically utilized during acute treatment, and transitioning to oral medications is preferred for home management. Initiating metoprolol succinate at target dose may not be immediate due to concerns regarding hemodynamic stability, especially after an acute episode. Starting sacubitril/valsartan may also be beneficial, but the initiation often depends on the patient's clinical status and prior medication regimen. Thus, while various options can support heart failure management, empagliflozin's specific benefits for preventing readmissions make it a strong choice upon discharge